NURSING 6005 CHAPTER 61: ESTROGENS AND PROGESTINS: Basic
Pharmacology and Noncontraceptive Applications
Test Bank
MULTIPLE CHOICE
1. A 50-year-old postmenopausal patient who has had a hysterectomy has moderate to severe
vasomotor symptoms and is discussing estrogen therapy (ET) with the nurse. The patient is
concerned about adverse effects of ET. The nurse will tell her that:
a. an estrogen-progesterone product will reduce side effects.
b. an intravaginal preparation may be best for her.
c. side effects of ET are uncommon among women her age.
d. transdermal preparations have fewer side effects.
ANS: D
Transdermal preparations of estrogen have fewer adverse effects, use lower doses of estrogen,
and have less fluctuation of estrogen levels than do oral preparations. Progesterone is
contraindicated in women who have undergone hysterectomy. Intravaginal preparations are
most useful for treating local estrogen deficiency such as vaginal and vulvar atrophy. Side
effects of ET are the same at the patient’s age as for other women using ET.
DIF: Cognitive Level: Application
REF: Estrogens | Routes of Administration | Transdermal TOP: Nursing Process: Planning
MSC: NCLEX Client Needs Category: Physiologic Integrity: Pharmacologic and Parenteral Therapies
2. A patient who is at risk for osteoporosis will begin taking the selective estrogen receptor
modulator raloxifene (Evista). Which statement will the nurse include when teaching this
patient about the medication?
a. Raloxifene reduces the risk of thromboembolism.
b. The drug is associated with an increased risk of breast cancer.
c. Use of this drug increases the risk of endometrial carcinoma.
d. Vasomotor symptoms are a common side effect of this drug.
ANS: D
Raloxifene can induce hot flashes in patients taking the drug. It increases the risk for
thromboembolism. It protects against breast cancer and does not pose a risk of uterine cancer.
DIF: Cognitive Level: Application
REF: Selective Estrogen Receptor Modulators (SERMS)
TOP: Nursing Process: Implementation
MSC: NCLEX Client Needs Category: Physiologic Integrity: Pharmacologic and Parenteral Therapies
3. A nurse provides teaching to a patient who has had a hysterectomy and is about to begin
hormone therapy to manage menopausal symptoms. Which statement by the patient indicates
understanding of the teaching?
a. “Because I am not at risk for uterine cancer, I can take hormones indefinitely.”
b. “I can take estrogen to reduce my risk of cardiovascular disease.”
c. “I should take the lowest effective dose for the shortest time needed.”
d. “I will need a progestin/estrogen combination since I have had a hysterectomy.”
Pharmacology and Noncontraceptive Applications
Test Bank
MULTIPLE CHOICE
1. A 50-year-old postmenopausal patient who has had a hysterectomy has moderate to severe
vasomotor symptoms and is discussing estrogen therapy (ET) with the nurse. The patient is
concerned about adverse effects of ET. The nurse will tell her that:
a. an estrogen-progesterone product will reduce side effects.
b. an intravaginal preparation may be best for her.
c. side effects of ET are uncommon among women her age.
d. transdermal preparations have fewer side effects.
ANS: D
Transdermal preparations of estrogen have fewer adverse effects, use lower doses of estrogen,
and have less fluctuation of estrogen levels than do oral preparations. Progesterone is
contraindicated in women who have undergone hysterectomy. Intravaginal preparations are
most useful for treating local estrogen deficiency such as vaginal and vulvar atrophy. Side
effects of ET are the same at the patient’s age as for other women using ET.
DIF: Cognitive Level: Application
REF: Estrogens | Routes of Administration | Transdermal TOP: Nursing Process: Planning
MSC: NCLEX Client Needs Category: Physiologic Integrity: Pharmacologic and Parenteral Therapies
2. A patient who is at risk for osteoporosis will begin taking the selective estrogen receptor
modulator raloxifene (Evista). Which statement will the nurse include when teaching this
patient about the medication?
a. Raloxifene reduces the risk of thromboembolism.
b. The drug is associated with an increased risk of breast cancer.
c. Use of this drug increases the risk of endometrial carcinoma.
d. Vasomotor symptoms are a common side effect of this drug.
ANS: D
Raloxifene can induce hot flashes in patients taking the drug. It increases the risk for
thromboembolism. It protects against breast cancer and does not pose a risk of uterine cancer.
DIF: Cognitive Level: Application
REF: Selective Estrogen Receptor Modulators (SERMS)
TOP: Nursing Process: Implementation
MSC: NCLEX Client Needs Category: Physiologic Integrity: Pharmacologic and Parenteral Therapies
3. A nurse provides teaching to a patient who has had a hysterectomy and is about to begin
hormone therapy to manage menopausal symptoms. Which statement by the patient indicates
understanding of the teaching?
a. “Because I am not at risk for uterine cancer, I can take hormones indefinitely.”
b. “I can take estrogen to reduce my risk of cardiovascular disease.”
c. “I should take the lowest effective dose for the shortest time needed.”
d. “I will need a progestin/estrogen combination since I have had a hysterectomy.”
